Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
The oral segment is expected to grow rapidly with CAGR of 22.9% during the forecast period due to its convenience and noninvasive administration, which improves patient observation
GLP-1 Therapy Through Telehealth Platforms May Align Well With People Who: Have a BMI of 30 or greater, or 27 or greater with weight-related health conditions: This generally aligns with clinical guidelines for considering medical weight management interventions alongside lifestyle modifications
The Mayo Clinic data specifically showed benefits with tirzepatide, while other studies demonstrated similar benefits with semaglutide
In addition, instead of thinness being a solution, it can come with the feeling that no matter how much weight you lose, you won't be satisfied
For various reasons physicians may be reluctant to prescribe these medications, however with a thoughtful and respectful discussion, you may be able to advocate for yourself for their use
US$ 24.49
US$ 21.86
US$ 20.31
